
(MedPage Today) — The FDA said it has received postmarketing reports of neutralizing antibodies to ADAMTS13, including one death, in patients with congenital thrombotic thrombocytopenic purpura (cTTP) who were treated with the recombinant ADAMTS13…
Source link : https://www.medpagetoday.com/hematologyoncology/hematology/118655
Author :
Publish date : 2025-11-21 20:16:00
Copyright for syndicated content belongs to the linked
Source.